| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mutation | 22 | 2025 | 2612 | 1.860 |
Why?
|
| Biomarkers, Tumor | 13 | 2025 | 507 | 1.680 |
Why?
|
| Adenocarcinoma | 6 | 2024 | 348 | 1.620 |
Why?
|
| High-Throughput Nucleotide Sequencing | 12 | 2025 | 313 | 1.610 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2021 | 105 | 1.190 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2025 | 309 | 0.890 |
Why?
|
| DNA Mutational Analysis | 11 | 2025 | 197 | 0.820 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2025 | 193 | 0.800 |
Why?
|
| Pancreatic Cyst | 2 | 2019 | 24 | 0.770 |
Why?
|
| Immunohistochemistry | 18 | 2025 | 896 | 0.770 |
Why?
|
| Myelodysplastic Syndromes | 5 | 2025 | 87 | 0.750 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2016 | 168 | 0.730 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2025 | 259 | 0.670 |
Why?
|
| Urothelium | 2 | 2020 | 22 | 0.670 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2021 | 43 | 0.650 |
Why?
|
| Proto-Oncogene Proteins B-raf | 6 | 2020 | 51 | 0.650 |
Why?
|
| Pancreatic Neoplasms | 2 | 2019 | 341 | 0.610 |
Why?
|
| Appendiceal Neoplasms | 1 | 2018 | 8 | 0.600 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2018 | 31 | 0.590 |
Why?
|
| Thymosin | 4 | 2007 | 8 | 0.580 |
Why?
|
| Hemangiosarcoma | 2 | 2015 | 25 | 0.580 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2015 | 108 | 0.570 |
Why?
|
| Papillomavirus Infections | 4 | 2025 | 129 | 0.570 |
Why?
|
| Middle Aged | 34 | 2025 | 17611 | 0.540 |
Why?
|
| Cytodiagnosis | 2 | 2016 | 46 | 0.530 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2021 | 74 | 0.510 |
Why?
|
| Pathology, Molecular | 1 | 2016 | 11 | 0.510 |
Why?
|
| Aged | 30 | 2025 | 14445 | 0.510 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2016 | 16 | 0.500 |
Why?
|
| Humans | 68 | 2025 | 63445 | 0.470 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2015 | 21 | 0.460 |
Why?
|
| Aged, 80 and over | 18 | 2025 | 5461 | 0.450 |
Why?
|
| Adult | 23 | 2025 | 16823 | 0.440 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 226 | 0.440 |
Why?
|
| Lung Diseases | 1 | 2016 | 183 | 0.440 |
Why?
|
| Simplexvirus | 5 | 1995 | 25 | 0.440 |
Why?
|
| Barrett Esophagus | 2 | 2011 | 30 | 0.430 |
Why?
|
| Prostatic Neoplasms | 4 | 2007 | 418 | 0.420 |
Why?
|
| Female | 36 | 2025 | 32877 | 0.420 |
Why?
|
| Human papillomavirus 16 | 2 | 2021 | 18 | 0.410 |
Why?
|
| Male | 38 | 2025 | 29888 | 0.410 |
Why?
|
| Anus Neoplasms | 2 | 2025 | 25 | 0.400 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2024 | 56 | 0.390 |
Why?
|
| Viral Proteins | 4 | 1995 | 263 | 0.380 |
Why?
|
| Human papillomavirus 18 | 1 | 2011 | 4 | 0.370 |
Why?
|
| Endothelial Cells | 3 | 2022 | 187 | 0.370 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2011 | 29 | 0.360 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2021 | 429 | 0.360 |
Why?
|
| Hemangioendothelioma, Epithelioid | 2 | 2021 | 7 | 0.360 |
Why?
|
| Stem Cell Transplantation | 2 | 2011 | 79 | 0.350 |
Why?
|
| Endothelium | 1 | 2010 | 21 | 0.340 |
Why?
|
| Myofibroblasts | 1 | 2010 | 16 | 0.340 |
Why?
|
| Sweat Gland Neoplasms | 2 | 2024 | 20 | 0.340 |
Why?
|
| Urine | 2 | 2021 | 45 | 0.340 |
Why?
|
| Neoplastic Stem Cells | 4 | 2019 | 203 | 0.330 |
Why?
|
| Neoplasm Staging | 6 | 2021 | 509 | 0.330 |
Why?
|
| Bone Marrow Cells | 1 | 2010 | 238 | 0.320 |
Why?
|
| Retinoblastoma Binding Proteins | 2 | 2019 | 6 | 0.300 |
Why?
|
| Receptor, ErbB-4 | 2 | 2019 | 10 | 0.300 |
Why?
|
| Adenoma, Oxyphilic | 2 | 2019 | 11 | 0.300 |
Why?
|
| Prognosis | 6 | 2025 | 1748 | 0.300 |
Why?
|
| Cyst Fluid | 2 | 2019 | 5 | 0.290 |
Why?
|
| Molecular Targeted Therapy | 3 | 2019 | 130 | 0.290 |
Why?
|
| Carcinoma | 2 | 2020 | 123 | 0.280 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2024 | 325 | 0.280 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2019 | 103 | 0.270 |
Why?
|
| Breast Neoplasms | 3 | 2018 | 1198 | 0.270 |
Why?
|
| Sensitivity and Specificity | 5 | 2017 | 1147 | 0.270 |
Why?
|
| Cell Fusion | 4 | 1995 | 37 | 0.260 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2019 | 219 | 0.260 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 160 | 0.260 |
Why?
|
| Diagnosis, Differential | 6 | 2019 | 978 | 0.260 |
Why?
|
| ras Proteins | 3 | 2016 | 77 | 0.250 |
Why?
|
| CD56 Antigen | 2 | 2021 | 17 | 0.250 |
Why?
|
| Repressor Proteins | 3 | 2024 | 346 | 0.250 |
Why?
|
| Skin Neoplasms | 2 | 2024 | 412 | 0.240 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 198 | 0.240 |
Why?
|
| MafG Transcription Factor | 2 | 2016 | 5 | 0.240 |
Why?
|
| Deubiquitinating Enzyme CYLD | 1 | 2025 | 5 | 0.230 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2025 | 8 | 0.230 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2021 | 206 | 0.230 |
Why?
|
| Histiocytic Sarcoma | 2 | 2016 | 4 | 0.220 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 454 | 0.220 |
Why?
|
| Neoplasm Grading | 3 | 2020 | 92 | 0.210 |
Why?
|
| Proctitis | 1 | 2023 | 6 | 0.210 |
Why?
|
| Dioxygenases | 1 | 2024 | 25 | 0.210 |
Why?
|
| Nevus | 1 | 2024 | 22 | 0.210 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2014 | 52 | 0.210 |
Why?
|
| Viral Envelope Proteins | 3 | 1993 | 103 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 188 | 0.210 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2025 | 172 | 0.210 |
Why?
|
| Chlamydia Infections | 1 | 2023 | 75 | 0.200 |
Why?
|
| CpG Islands | 2 | 2014 | 216 | 0.200 |
Why?
|
| Survival Rate | 4 | 2020 | 851 | 0.200 |
Why?
|
| Cell Cycle Proteins | 1 | 2025 | 396 | 0.190 |
Why?
|
| Gene Silencing | 2 | 2016 | 400 | 0.190 |
Why?
|
| Cytogenetic Analysis | 2 | 2020 | 25 | 0.190 |
Why?
|
| beta Catenin | 2 | 2021 | 96 | 0.190 |
Why?
|
| Colorectal Neoplasms | 2 | 2016 | 276 | 0.190 |
Why?
|
| Lymphatic Vessels | 1 | 2022 | 32 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 4 | 2016 | 517 | 0.180 |
Why?
|
| Uterine Neoplasms | 2 | 2020 | 34 | 0.180 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 1094 | 0.180 |
Why?
|
| Vascular Neoplasms | 1 | 2021 | 17 | 0.180 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2021 | 11 | 0.180 |
Why?
|
| Melanoma | 2 | 2016 | 331 | 0.180 |
Why?
|
| Anal Canal | 1 | 2021 | 36 | 0.170 |
Why?
|
| Endometrial Neoplasms | 2 | 2020 | 61 | 0.170 |
Why?
|
| Antibodies, Bispecific | 1 | 2021 | 31 | 0.170 |
Why?
|
| Urinary Bladder | 1 | 2021 | 45 | 0.170 |
Why?
|
| Hodgkin Disease | 2 | 2013 | 55 | 0.170 |
Why?
|
| Urologic Neoplasms | 1 | 2020 | 18 | 0.170 |
Why?
|
| Leukemia, Neutrophilic, Chronic | 1 | 2020 | 4 | 0.170 |
Why?
|
| Leukocytosis | 1 | 2020 | 15 | 0.170 |
Why?
|
| Adenosarcoma | 1 | 2020 | 4 | 0.170 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2020 | 6 | 0.160 |
Why?
|
| Ampulla of Vater | 1 | 2020 | 12 | 0.160 |
Why?
|
| Lymphoma, B-Cell | 2 | 2013 | 61 | 0.160 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2020 | 21 | 0.160 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2020 | 32 | 0.160 |
Why?
|
| DNA-Binding Proteins | 3 | 2024 | 1186 | 0.160 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2019 | 15 | 0.160 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2019 | 15 | 0.160 |
Why?
|
| Nuclear Proteins | 2 | 2014 | 778 | 0.160 |
Why?
|
| Oncogenes | 2 | 2018 | 68 | 0.160 |
Why?
|
| Thiazolidines | 1 | 2019 | 14 | 0.160 |
Why?
|
| Biphenyl Compounds | 1 | 2019 | 32 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2020 | 217 | 0.150 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 2458 | 0.150 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 10 | 0.150 |
Why?
|
| Pyrimidines | 2 | 2022 | 137 | 0.150 |
Why?
|
| Pancreas | 1 | 2019 | 151 | 0.150 |
Why?
|
| Animals | 18 | 2022 | 20660 | 0.150 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2019 | 35 | 0.150 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2011 | 68 | 0.150 |
Why?
|
| Receptors, Somatomedin | 1 | 2018 | 10 | 0.140 |
Why?
|
| Young Adult | 5 | 2025 | 4694 | 0.140 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 207 | 0.140 |
Why?
|
| DNA Methylation | 3 | 2016 | 292 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 165 | 0.140 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2008 | 46 | 0.140 |
Why?
|
| Carcinoma, Lobular | 1 | 2018 | 26 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 415 | 0.140 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2018 | 55 | 0.140 |
Why?
|
| Lymph Nodes | 3 | 2018 | 226 | 0.140 |
Why?
|
| Immunophenotyping | 5 | 2021 | 196 | 0.130 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 322 | 0.130 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2016 | 4 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 2 | 2016 | 168 | 0.130 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2016 | 8 | 0.130 |
Why?
|
| Disease Progression | 5 | 2024 | 1172 | 0.130 |
Why?
|
| 5-Methylcytosine | 1 | 2016 | 21 | 0.130 |
Why?
|
| Molecular Sequence Data | 6 | 2014 | 1991 | 0.130 |
Why?
|
| Lung Neoplasms | 2 | 2014 | 674 | 0.130 |
Why?
|
| Eyelid Neoplasms | 1 | 2016 | 9 | 0.130 |
Why?
|
| Gene Deletion | 1 | 2018 | 309 | 0.130 |
Why?
|
| Lipase | 1 | 2017 | 50 | 0.130 |
Why?
|
| Tetrasomy | 1 | 2016 | 3 | 0.130 |
Why?
|
| Laboratories | 1 | 2016 | 27 | 0.130 |
Why?
|
| Mucins | 1 | 2016 | 27 | 0.130 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2016 | 15 | 0.130 |
Why?
|
| Sarcoma | 1 | 2016 | 36 | 0.120 |
Why?
|
| Neoplasm Metastasis | 3 | 2020 | 200 | 0.120 |
Why?
|
| Epigenesis, Genetic | 2 | 2016 | 385 | 0.120 |
Why?
|
| Liver | 1 | 2020 | 855 | 0.120 |
Why?
|
| Retrospective Studies | 4 | 2023 | 6657 | 0.120 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2015 | 43 | 0.120 |
Why?
|
| Recombinant Proteins | 4 | 2005 | 702 | 0.120 |
Why?
|
| PAX5 Transcription Factor | 2 | 2012 | 13 | 0.120 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2015 | 26 | 0.120 |
Why?
|
| Vero Cells | 5 | 1995 | 80 | 0.110 |
Why?
|
| Up-Regulation | 5 | 2016 | 374 | 0.110 |
Why?
|
| Biopsy | 1 | 2016 | 443 | 0.110 |
Why?
|
| Herpesvirus 1, Human | 1 | 1995 | 82 | 0.110 |
Why?
|
| DNA | 1 | 2019 | 837 | 0.110 |
Why?
|
| Fixatives | 1 | 2014 | 16 | 0.110 |
Why?
|
| Fatal Outcome | 4 | 2020 | 124 | 0.110 |
Why?
|
| Glycoproteins | 2 | 1993 | 187 | 0.110 |
Why?
|
| Benzamides | 1 | 2014 | 65 | 0.110 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2014 | 10 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2013 | 448 | 0.110 |
Why?
|
| Genes, ras | 1 | 2014 | 27 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2007 | 345 | 0.110 |
Why?
|
| Piperazines | 1 | 2014 | 81 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2019 | 3293 | 0.110 |
Why?
|
| Vascular Diseases | 1 | 2015 | 81 | 0.110 |
Why?
|
| Mice | 7 | 2022 | 10844 | 0.110 |
Why?
|
| Amino Acid Sequence | 5 | 2014 | 1592 | 0.110 |
Why?
|
| DNA Mismatch Repair | 1 | 2014 | 35 | 0.100 |
Why?
|
| Transplantation, Homologous | 2 | 2011 | 245 | 0.100 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2013 | 39 | 0.100 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2013 | 7 | 0.100 |
Why?
|
| Mastocytosis, Systemic | 1 | 2013 | 5 | 0.100 |
Why?
|
| Breast | 1 | 2015 | 183 | 0.100 |
Why?
|
| Clonal Evolution | 1 | 2013 | 6 | 0.100 |
Why?
|
| Mast Cells | 1 | 2013 | 39 | 0.100 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2012 | 25 | 0.100 |
Why?
|
| Lymphoma, Follicular | 1 | 2013 | 16 | 0.100 |
Why?
|
| Melanocytes | 1 | 2013 | 77 | 0.100 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2012 | 51 | 0.100 |
Why?
|
| Bone Marrow Transplantation | 1 | 2013 | 139 | 0.100 |
Why?
|
| Adolescent | 3 | 2023 | 6245 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 49 | 0.100 |
Why?
|
| Carboplatin | 1 | 2012 | 43 | 0.100 |
Why?
|
| Boronic Acids | 1 | 2012 | 28 | 0.090 |
Why?
|
| src-Family Kinases | 1 | 2012 | 64 | 0.090 |
Why?
|
| Pyrazines | 1 | 2012 | 34 | 0.090 |
Why?
|
| Viral Fusion Proteins | 1 | 1992 | 54 | 0.090 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2011 | 21 | 0.090 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2011 | 14 | 0.090 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2011 | 25 | 0.090 |
Why?
|
| Graft vs Host Disease | 1 | 2013 | 113 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 525 | 0.090 |
Why?
|
| Cervix Uteri | 1 | 2011 | 60 | 0.090 |
Why?
|
| Herpesvirus 4, Human | 1 | 2013 | 196 | 0.090 |
Why?
|
| Smoking | 1 | 2016 | 866 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 198 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 281 | 0.090 |
Why?
|
| Metaplasia | 1 | 2010 | 18 | 0.090 |
Why?
|
| Phenotype | 3 | 2025 | 1207 | 0.080 |
Why?
|
| Stromal Cells | 1 | 2010 | 68 | 0.080 |
Why?
|
| Esophageal Neoplasms | 1 | 2011 | 83 | 0.080 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 166 | 0.080 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 2 | 2024 | 28 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 238 | 0.080 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 878 | 0.080 |
Why?
|
| Genes, Viral | 3 | 1995 | 57 | 0.080 |
Why?
|
| Cell Line, Tumor | 4 | 2016 | 1469 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2008 | 27 | 0.070 |
Why?
|
| Trisomy | 1 | 2008 | 21 | 0.070 |
Why?
|
| Epithelial Cells | 1 | 2010 | 390 | 0.070 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2007 | 2 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2007 | 17 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 2187 | 0.070 |
Why?
|
| Imatinib Mesylate | 2 | 2019 | 34 | 0.070 |
Why?
|
| Recurrence | 2 | 2008 | 641 | 0.070 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 67 | 0.070 |
Why?
|
| Collagen | 1 | 2007 | 123 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 126 | 0.060 |
Why?
|
| Liposarcoma | 1 | 2006 | 8 | 0.060 |
Why?
|
| Transcription Factors | 4 | 2021 | 1513 | 0.060 |
Why?
|
| Cell Membrane | 2 | 2001 | 496 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 2 | 2005 | 673 | 0.060 |
Why?
|
| United States | 2 | 2016 | 7845 | 0.060 |
Why?
|
| Consensus Sequence | 1 | 2005 | 30 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 2006 | 140 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2005 | 35 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 1 | 2005 | 76 | 0.060 |
Why?
|
| Conserved Sequence | 1 | 2005 | 173 | 0.060 |
Why?
|
| Prostatectomy | 1 | 2005 | 99 | 0.060 |
Why?
|
| MutL Protein Homolog 1 | 2 | 2014 | 27 | 0.060 |
Why?
|
| Protein Structure, Secondary | 1 | 2005 | 260 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2019 | 936 | 0.050 |
Why?
|
| Granulation Tissue | 1 | 2023 | 3 | 0.050 |
Why?
|
| Ulcer | 1 | 2023 | 14 | 0.050 |
Why?
|
| Alleles | 1 | 2025 | 448 | 0.050 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2024 | 83 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 1654 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2008 | 348 | 0.050 |
Why?
|
| Gene Rearrangement | 2 | 2014 | 41 | 0.050 |
Why?
|
| Basement Membrane | 1 | 2022 | 25 | 0.050 |
Why?
|
| Adenoviridae | 2 | 1993 | 127 | 0.050 |
Why?
|
| Lymphatic System | 1 | 2022 | 19 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2013 | 201 | 0.050 |
Why?
|
| Pyridones | 1 | 2022 | 40 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2021 | 3035 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2005 | 1119 | 0.050 |
Why?
|
| Glycosylation | 2 | 1992 | 138 | 0.050 |
Why?
|
| Blast Crisis | 1 | 2021 | 10 | 0.050 |
Why?
|
| Synaptophysin | 1 | 2021 | 6 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2021 | 52 | 0.040 |
Why?
|
| Chromogranins | 1 | 2021 | 12 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2021 | 39 | 0.040 |
Why?
|
| Epidermal Growth Factor | 1 | 2001 | 47 | 0.040 |
Why?
|
| Cadherins | 1 | 2021 | 80 | 0.040 |
Why?
|
| Urinalysis | 1 | 2020 | 38 | 0.040 |
Why?
|
| Adherens Junctions | 1 | 2020 | 9 | 0.040 |
Why?
|
| Embryo Loss | 1 | 2020 | 12 | 0.040 |
Why?
|
| Gain of Function Mutation | 1 | 2020 | 15 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2014 | 363 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2021 | 101 | 0.040 |
Why?
|
| Heparin | 1 | 2001 | 116 | 0.040 |
Why?
|
| Trans-Activators | 2 | 2012 | 311 | 0.040 |
Why?
|
| Microscopy | 1 | 2020 | 91 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2021 | 347 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2001 | 276 | 0.040 |
Why?
|
| Cell Communication | 1 | 2020 | 130 | 0.040 |
Why?
|
| Mass Screening | 1 | 2005 | 691 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 1380 | 0.040 |
Why?
|
| bcl-Associated Death Protein | 1 | 2019 | 10 | 0.040 |
Why?
|
| Leukemia, Experimental | 1 | 2019 | 19 | 0.040 |
Why?
|
| STAT Transcription Factors | 1 | 2019 | 17 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2019 | 83 | 0.040 |
Why?
|
| Protein Isoforms | 3 | 2007 | 197 | 0.040 |
Why?
|
| Actins | 1 | 2000 | 259 | 0.040 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2018 | 30 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2012 | 213 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2018 | 72 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2000 | 383 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 1277 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 278 | 0.030 |
Why?
|
| Amylases | 1 | 2017 | 12 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2017 | 33 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2018 | 186 | 0.030 |
Why?
|
| Jaw | 1 | 2016 | 4 | 0.030 |
Why?
|
| Merkel cell polyomavirus | 1 | 2016 | 5 | 0.030 |
Why?
|
| History, 17th Century | 1 | 2016 | 6 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 50 | 0.030 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2016 | 41 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2001 | 707 | 0.030 |
Why?
|
| Brain Neoplasms | 2 | 2011 | 308 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 864 | 0.030 |
Why?
|
| Giant Cells | 1 | 1995 | 15 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1995 | 52 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2016 | 232 | 0.030 |
Why?
|
| Hexosaminidases | 1 | 1995 | 6 | 0.030 |
Why?
|
| Open Reading Frames | 1 | 1995 | 84 | 0.030 |
Why?
|
| Oligosaccharides | 1 | 1995 | 54 | 0.030 |
Why?
|
| Nuclear Envelope | 1 | 1995 | 49 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 1995 | 251 | 0.030 |
Why?
|
| raf Kinases | 1 | 2014 | 4 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1995 | 383 | 0.030 |
Why?
|
| Plasmids | 1 | 1995 | 292 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2014 | 20 | 0.030 |
Why?
|
| Alcohols | 1 | 2014 | 13 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2014 | 24 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2014 | 31 | 0.030 |
Why?
|
| Genome, Viral | 1 | 1995 | 136 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2014 | 57 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 1039 | 0.030 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2014 | 39 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 1995 | 173 | 0.030 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2014 | 34 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2014 | 78 | 0.030 |
Why?
|
| Papanicolaou Test | 1 | 2014 | 43 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1995 | 245 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 71 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2014 | 16 | 0.030 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2014 | 17 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2014 | 102 | 0.030 |
Why?
|
| Child | 1 | 2023 | 4526 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 202 | 0.030 |
Why?
|
| Viral Plaque Assay | 1 | 1993 | 16 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2014 | 114 | 0.030 |
Why?
|
| Antibodies, Viral | 2 | 1993 | 327 | 0.030 |
Why?
|
| Fibroblasts | 1 | 1995 | 394 | 0.030 |
Why?
|
| Abnormal Karyotype | 1 | 2013 | 2 | 0.030 |
Why?
|
| Viral Structural Proteins | 1 | 1993 | 17 | 0.030 |
Why?
|
| Time Factors | 2 | 2016 | 3768 | 0.030 |
Why?
|
| Anemia, Hemolytic | 1 | 2013 | 12 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2014 | 583 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2013 | 33 | 0.020 |
Why?
|
| Clone Cells | 1 | 2013 | 114 | 0.020 |
Why?
|
| Tandem Repeat Sequences | 1 | 2012 | 26 | 0.020 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2012 | 26 | 0.020 |
Why?
|
| Base Sequence | 1 | 1995 | 1331 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2012 | 34 | 0.020 |
Why?
|
| Cytarabine | 1 | 2012 | 36 | 0.020 |
Why?
|
| Cell-Free System | 1 | 1992 | 31 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2013 | 75 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 883 | 0.020 |
Why?
|
| Genes, abl | 1 | 2012 | 9 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2012 | 17 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2012 | 31 | 0.020 |
Why?
|
| K562 Cells | 1 | 2012 | 58 | 0.020 |
Why?
|
| Precipitin Tests | 1 | 1992 | 77 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 242 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 622 | 0.020 |
Why?
|
| Bortezomib | 1 | 2012 | 56 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 1993 | 2157 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2012 | 59 | 0.020 |
Why?
|
| Axilla | 1 | 2011 | 18 | 0.020 |
Why?
|
| Pelvic Neoplasms | 1 | 2011 | 10 | 0.020 |
Why?
|
| Groin | 1 | 2011 | 15 | 0.020 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2011 | 16 | 0.020 |
Why?
|
| CDX2 Transcription Factor | 1 | 2011 | 5 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2011 | 8 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 373 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2013 | 270 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1995 | 629 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2011 | 46 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 676 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2011 | 127 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 77 | 0.020 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 103 | 0.020 |
Why?
|
| Bile Acids and Salts | 1 | 2011 | 23 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 1992 | 137 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2013 | 276 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 1408 | 0.020 |
Why?
|
| Hysterectomy | 1 | 2011 | 69 | 0.020 |
Why?
|
| Karyotyping | 1 | 2011 | 48 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1992 | 197 | 0.020 |
Why?
|
| Biological Transport | 1 | 1992 | 291 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 465 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2012 | 284 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1992 | 612 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 319 | 0.020 |
Why?
|
| Palliative Care | 1 | 2013 | 230 | 0.020 |
Why?
|
| RNA Interference | 1 | 2014 | 618 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 988 | 0.020 |
Why?
|
| Rats | 2 | 2007 | 1980 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 1992 | 320 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2001 | 456 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 268 | 0.020 |
Why?
|
| Pneumonia | 1 | 2013 | 291 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 352 | 0.020 |
Why?
|
| DNA Damage | 1 | 2011 | 287 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2012 | 5680 | 0.020 |
Why?
|
| Protein Conformation | 1 | 1992 | 779 | 0.020 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2008 | 5 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2001 | 489 | 0.020 |
Why?
|
| Sepsis | 1 | 2013 | 289 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 1558 | 0.020 |
Why?
|
| Transfection | 2 | 2001 | 694 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 921 | 0.020 |
Why?
|
| Binding Sites | 2 | 2001 | 905 | 0.020 |
Why?
|
| Cell Line | 1 | 1992 | 2040 | 0.020 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2007 | 9 | 0.020 |
Why?
|
| Parvovirus B19, Human | 1 | 2007 | 5 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 1993 | 879 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 2109 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 663 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2007 | 299 | 0.020 |
Why?
|
| Antibodies | 1 | 2007 | 183 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2006 | 17 | 0.020 |
Why?
|
| Protein Binding | 2 | 2001 | 1603 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2006 | 519 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 3396 | 0.010 |
Why?
|
| HIV Infections | 1 | 2011 | 969 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2001 | 12 | 0.010 |
Why?
|
| Etoposide | 1 | 2001 | 34 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2001 | 41 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2007 | 1537 | 0.010 |
Why?
|
| Ubiquitins | 1 | 2001 | 41 | 0.010 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2001 | 67 | 0.010 |
Why?
|
| COS Cells | 1 | 2001 | 175 | 0.010 |
Why?
|
| CHO Cells | 1 | 2001 | 189 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2001 | 209 | 0.010 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2001 | 78 | 0.010 |
Why?
|
| Cricetinae | 1 | 2001 | 367 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2001 | 235 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 450 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2000 | 248 | 0.010 |
Why?
|
| Cell Survival | 1 | 2001 | 575 | 0.010 |
Why?
|
| Cell Movement | 1 | 2000 | 453 | 0.010 |
Why?
|
| Apoptosis | 1 | 2001 | 1079 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 1993 | 63 | 0.010 |
Why?
|
| Adsorption | 1 | 1993 | 84 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 1993 | 89 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1993 | 490 | 0.010 |
Why?
|
| Endocytosis | 1 | 1993 | 152 | 0.010 |
Why?
|
| Virus Replication | 1 | 1993 | 321 | 0.010 |
Why?
|